RESUMEN
The Coronavirus disease-2019 (COVID-19) pandemic caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), has become a dire global health concern. The development of vaccines with high immunogenicity and safety is crucial for control of the global COVID-19 pandemic and prevention of further illness and fatalities. Here, we report development of SARS-CoV-2 vaccine candidate, Nanocovax, based on recombinant protein production of the extracellular (soluble) portion of the S protein of SARS-CoV-2. The results showed that Nanocovax induced high levels of S protein-specific IgG, as well neutralizing antibody in three animal models including Balb/C mice, Syrian hamsters, and non-human primate (Macaca leonina). In addition, the viral challenge study using the hamster model showed that Nanocovax protected the upper respiratory tract from SARS-CoV-2 infection. No adverse effects were induced by Nanocovax in swiss mice (Musmusculus var. Albino), Rats (Rattus norvegicus), and New Zealand rabbits. These pre-clinical results indicated that Nanocovax is safe and effective.
RESUMEN
We prepared ZnO nanocomposites with WO3 or CuO nanostructures to improve the photocatalytic performance of ZnO nanostructures. Characterization of the nanocomposites using scanning electron microscopy, x-ray diffraction, UV-vis spectrometry and photoluminescence revealed the morphologies and wide light absorption range of the materials. The highest current densities of WO3/ZnO and CuO/ZnO nanocomposites were 1.28 mA cm-2 and 2.49 mA cm-2 at 1.23 V (versus a reversible hydrogen electrode) under AM 1.5 100 mW cm-2, which are ~1.2- and 3.5-fold greater than those of bare ZnO nanostructures, respectively. The easy fabrication process suggests that nanocomposites with narrow bandgap materials, such as WO3 and CuO, will improve the performance of electrochemical and optoelectrical devices such as dye-sensitized solar cells and biosensors.